Immunoassay approach for diagnosis of exposure to pyrrolizidine alkaloids

References

• Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids—genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36:1–55.
   PubMed Web of Science ®Google Scholar
• Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie. 2000;55:711–726.
   PubMed Web of Science ®Google Scholar
• Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. Academic Press, New York; 1986.
   Google Scholar
• Stegelmeier BL, Edgar JA, Colegate SM, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins. 1999;8:95–116.
   PubMedGoogle Scholar
• Li N, Xia Q, Ruan J, et al. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. Curr Drug Metab. 2011;12:823–834.
   PubMed Web of Science ®Google Scholar
• Ruan J, Liao C, Ye Y, et al. Lack of metabolic activation and predominant formation of an excreted metabolite of nontoxic platynecine-type pyrrolizidine alkaloids. Chem Res Toxicol. 2014;27:7–16.
   PubMed Web of Science ®Google Scholar
• Yang M, Ruan J, Fu PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact. 2016;243:119–126.
   PubMed Web of Science ®Google Scholar
• Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13:33–39.
   PubMed Web of Science ®Google Scholar
• Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54:666–673.
   PubMed Web of Science ®Google Scholar
• Li YH, Tai WC, Xue JY, et al. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats. Chem Res Toxicol. 2015;28:1715–1727.
   PubMed Web of Science ®Google Scholar
• Willmot F, Robertson G. Senecio disease or cirrhosis of the liver due to Senecio poisoning. Lancet. 1920;2:848–849.
   Google Scholar
• Dai N, Yu YC, Ren TH, et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol. 2007;13:1628–1631.
   PubMed Web of Science ®Google Scholar
• Mohabbat O, Younos MS, Merzad AA, et al. An outbreak of hepatic veno-occlusive disease in North-Western Afghanistan. Lancet. 1976;2:269–271.
   PubMed Web of Science ®Google Scholar
• Bodi D, Ronczka S, Gottschalk C, et al. Determination of pyrrolizidine alkaloids in tea, herbal drugs and honey. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31:1886–1895.
   PubMed Web of Science ®Google Scholar
• Edgar JA, Colegate SM, Boppre M, et al. Pyrrolizidine alkaloids in food: a spectrum of potential health consequences. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011;28:308–324.
   PubMed Web of Science ®Google Scholar
• Ma B, Li N, Lin G. Importance of metabolic activation study to the safe use of Chinese herbal medicines. Current Drug Metabolism. 2012;13:652–658.
   PubMed Web of Science ®Google Scholar
• Ruan J, Gao H, Li N, et al. Blood pyrrole-protein adducts-a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33:404–421.
   PubMed Web of Science ®Google Scholar
• Elvidge T, Matthews IP, Gregory C, et al. Feasibility of using biomarkers in blood serum as markers of effect following exposure of the lungs to particulate matter air pollution. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31:1–44.
   PubMed Web of Science ®Google Scholar
• Chen M, Li L, Zhong D, et al. 9-Glutathionyl-6, 7-dihydro-1-hydroxymethyl-5 H-pyrrolizine is the major pyrrolic glutathione conjugate of Retronecine-type pyrrolizidine alkaloids in liver microsomes and in rats. Chem Res Toxicol. 2016;29:180–189.
   PubMed Web of Science ®Google Scholar
• Zhu L, Li N, Ruan FP, et al. Chemical diversity investigation of hepatotoxic pyrrolizidine alkaloids in Qianliguang (Senecio scandens) and related species by UHPLC-QTOF-MS. WJTCM. 2015;1:1–11.
   Google Scholar
• Zhu L, Ruan JQ, Li N, et al. A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. Food Chem. 2016;194:1320–1328.
   PubMed Web of Science ®Google Scholar
• Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature. 1968;217:723–728.
   PubMed Web of Science ®Google Scholar
• He X, Xia Q, Ma L, et al. 7-cysteine-pyrrole conjugate: A new potential DNA reactive metabolite of pyrrolizidine alkaloids. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2016;34:57–76.
   PubMed Web of Science ®Google Scholar
• Lin G, Zhou KY, Zhao XG, et al. Determination of hepatotoxic pyrrolizidine alkaloids by on-line high performance liquid chromatography mass spectrometry with an electrospray interface. Rapid Commun Mass Spectrom. 1998;12:1445–1456.
   PubMed Web of Science ®Google Scholar
• Wang CC, Xia Q, Li M, et al. Metabolic activation of pyrrolizidine alkaloids leading to phototoxicity and photogenotoxicity in human HaCaT keratinocytes. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014;32:362–384.
   PubMed Web of Science ®Google Scholar
• Xia QS, Zhao YW, Von Tungeln LS, et al. Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity. Chem Res Toxicol. 2013;26:1384–1396.
   PubMed Web of Science ®Google Scholar
• Wang H, Feng Y, Wang Q, et al. Cysteine-based protein adduction by epoxide-derived metabolite(s) of Benzbromarone. Chem Res Toxicol. 2016;29:2145–2152.
   PubMed Web of Science ®Google Scholar
• Shen S, Zhang F, Zeng S, et al. Development of enantioselective polyclonal antibodies to detect styrene oxide protein adducts. Anal Chem. 2009;81:2668–2677.
   PubMed Web of Science ®Google Scholar
• Yuan W, Chung J, Gee S, et al. Development of polyclonal antibodies for the detection of styrene oxide modified proteins. Chem Res Toxicol. 2007;20:316–321.
   PubMed Web of Science ®Google Scholar
• Lee ST, Schoch TK, Stegelmeier BL, et al. Development of enzyme-linked immunosorbent assays for the hepatotoxic alkaloids riddelliine and riddelliine N-oxide. J Agric Food Chem. 2001;49:4144–4151.
   PubMed Web of Science ®Google Scholar
• Zundorf I, Wiedenfeld H, Roder E, et al. Generation and characterization of monoclonal antibodies against the pyrrolizidine alkaloid retrorsine. Planta Med. 1998;64:259–263.
   PubMed Web of Science ®Google Scholar
• Oplatowska M, Elliott CT, Huet AC, et al. Development and validation of a rapid multiplex ELISA for pyrrolizidine alkaloids and their N-oxides in honey and feed. Anal Bioanal Chem. 2014;406:757–770.
   PubMed Web of Science ®Google Scholar
• Li YH, Kan WL, Li N, et al. Assessment of pyrrolizidine alkaloid-induced toxicity in an in vitro screening model. J Ethnopharmacol. 2013;150:560–567.
   PubMed Web of Science ®Google Scholar
• Lin G, Cui YY, Hawes EM. Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos. 2000;28:1475–1483.
   PubMed Web of Science ®Google Scholar
• Lin G, Zheng J, Li N. Method and assay kit for detection of toxicity induced by pyrrolizidine alkaloids. U.S. Patent 9,056,916. 2015-6-16; 2015.
   Google Scholar
• De Jonge ME, Huitema AD, Beijnen JH, et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer. 2006;94:1226–1230.
   PubMed Web of Science ®Google Scholar
• Ruan JQ, Yang MB, Fu P, et al. Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol. 2014;27:1030–1039.
   PubMed Web of Science ®Google Scholar
• Li W, Wang K, Lin G, et al. Lysine adduction by reactive metabolite(s) of monocrotaline. Chem Res Toxicol. 2016;29:333–341.
   PubMed Web of Science ®Google Scholar
• Roberts DW, Pumford NR, Potter DW, et al. A sensitive immunochemical assay for acetaminophen-protein adducts. J Pharmacol Exp Ther. 1987;241:527–533.
   PubMed Web of Science ®Google Scholar
• Bartolone JB, Birge RB, Bulera SJ, et al. Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins. Toxicol Appl Pharmacol. 1992;113:19–29.
   PubMed Web of Science ®Google Scholar
• Satoh H, Fukuda Y, Anderson DK, et al. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther. 1985;233:857–862.
   PubMed Web of Science ®Google Scholar
• Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980;303:66–71.
   PubMed Web of Science ®Google Scholar
• Kleiner HE, Rivera MI, Pumford NR, et al. Immunochemical detection of quinol–thioether-derived protein adducts. Chem Res Toxicol. 1998;11:1283–1290.
   PubMed Web of Science ®Google Scholar
• Zheng J, Hammock BD. Development of polyclonal antibodies for detection of protein modification by 1,2-naphthoquinone. Chem Res Toxicol. 1996;9:904–909.
   PubMed Web of Science ®Google Scholar
• Halmes NC, McMillan DC, Oatis JE, Jr., et al. Immunochemical detection of protein adducts in mice treated with trichloroethylene. Chem Res Toxicol. 1996;9:451–456.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huo JR. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010;68:252–260.
   PubMed Web of Science ®Google Scholar